Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis. (ADhere)

J2T-DM-KGAD -

The study is designed to evaluate the safety and efficacy of lebrikizumab when used in combination with topical corticosteroid (TCS) treatment compared with placebo in combination with TCS treatment for moderate-to-severe atopic dermatitis.

Trial Summary

Age Range
≥12 years
Conditions the trial is for
Atopic Dermatitis
What the trial is testing?
Lebrikizumab, Topical corticosteroid
Could I receive a Placebo?
Yes
Enrollment Goal
228
Trial Dates
Feb 3, 2020 - Sep 16, 2021
How long will I be in the trial?
The study will last about 16 weeks and may include up to 11 visits.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must have atopic dermatitis that has been present for at least one year

  • Participants must have had an inadequate response to topical medications (medications applied to the skin)

Participants Must Not:

  • Participants must not have received a vaccine within 12 weeks of starting the study

  • Participants must not have hepatitis

  • Participants must not have a history of HIV

  • Participants must not have a history of cancer within 5 years

  • Women must not be pregnant, breastfeeding or plan to become pregnant during the study

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.